Cáncer de estómago

  1. Villaverde, R. Molina
  2. Gordo, A.M. Jiménez
  3. del Moral, A. San Juan
  4. Álvarez-Mon Soto, M.
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2017

Issue Title: Enfermedades oncológicas (II) Tumores digestivos

Series: 12

Issue: 32

Pages: 1904-1910

Type: Article

DOI: 10.1016/J.MED.2017.04.011 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

Abstract Background Stomach cancer is the second leading cause of death from cancer worldwide. The incidence of stomach cancer has varied significantly in the last century. The most common symptoms of stomach cancer are bleeding, epigastric pain, anorexia and dyspepsia. Diagnosis The test of choice for diagnosing stomach cancer is upper endoscopy with direct biopsy. Treatment The only curative treatment option is surgical resection. Perioperative chemotherapy, chemoradiation therapy and adjuvant chemotherapy have shown their efficacy in stages I to III of stomach cancer in various randomised studies. For advanced disease, various combinations of chemotherapy are normally employed. The addition of trastuzumab to first-line chemotherapy of disseminated disease has increased the efficacy of chemotherapy in tumours that overexpress human epidermal growth factor receptor 2

Bibliographic References

  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
  • Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40(3):250-60.
  • Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784-89.
  • Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Metaanalysis of the relationship between CagA seropositivity and gastric cancer. Gastroenterology. 2003;125:1636-44.
  • Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer. 2007;10(1):75-83.
  • Guilford P, Humar B, Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer. 2010;13(1):1-10.
  • Ying R, Ngeow J. Hereditary diffuse gastric cancer: What the clinician should know. World J Gastrointest Oncol. 2015;7(9):153-60.
  • Berlth F, Bollschweiler E, Drebber U, Hoelscher A, Moenig S. Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value. World J Gastroenterol. 2014;20(19):5679-84.
  • Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003;14(2):1-6.
  • Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med. 1995;333(1): 32-41.
  • Dooley CP, Larson AW, Stace NH, Renner IG, Valenzuela JE, Eliasoph J. Double-contrast barium meal and upper gastrointestinal endosco-py. A comparative study. Ann Intern Med. 1984;101(4):538-45.
  • Weber WA, Ott K. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol. 2007;25:2017-116.
  • Sarela AI, Lefkowitz R, Brennan MF, Karpeh MS. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg. 2006;191:134-8.
  • Edge SN, Byrd DR, Compton CC. AJCC Cancer Staging Manual. 7ª ed. New York: Springer; 2010.
  • Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A. The diagnosis and management of gastric cancer: expert dis-cussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol. 2011;22Suppl5:v1-v9.
  • Okines A, Verheij M, Allum W, Cunningham D, Cervantes A. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol. 2010;21Suppl5:v50-v54.
  • Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - Differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 2012;48(16):2941-53.
  • Takeshita K, Tani M, Inoue H, Saeki I, Hayashi S, Honda T. Endoscopic treatment of early oesophageal or gastric cancer. Gut. 1997;40(1): 123-7.
  • Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Masashi F, Nashimoto A. Adjuvant chemotherapy for gastric cancer with S1, an oral fluoropyrimidine. N Engl Med. 2007;357:1810-20.
  • Paoletti X, Obak K, Burzykowski T, Michaels S, Ohashi Y, Pignon P. Benefit of adjuvant chemotherapy for resectable gastric can-cer: a meta-analysis. JAMA. 2010;303(17):1729-37.
  • Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stem-mermann GN. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725-30.
  • Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20.
  • Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trials. J Clin Oncol. 2011;29(13):1715-21.
  • Sym SJ, Chang HM, Ryu MH, Lee JL, Kim TW, Yook JH. Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. Am Surg Oncol. 2010;17(4):1024-32.
  • Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-7.
  • Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46.
  • Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A. Trastuzumab in combination with chemotherapy versus chemothe-rapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a phase 3, open label, randomised controlled trial. Lancet. 2010;376(9742):687-97.
  • Young K, Smyth E, Chau I. Ramucirumab for advanced gastric cancer or gastroesophageal junction adenocarcinoma. Therap Adv Gastroenterol. 2015;8(6):373-83.
  • Kim HS, Kim HJ, Kim SY, Kim TY, Lee KW, Baek K. Second line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta- analysis. Ann Oncol. 2013;1-5.
  • Farré J, Bretcha P, Martín M, Sureda M, Brugarolas A. Carcinomatosis peritoneal. Quimioterapia intraperitoneal con hipertermia. Oncología. 2014;27(4):262-6.
Data source: Dialnet